{"nctId":"NCT01545388","briefTitle":"Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)","startDateStruct":{"date":"2012-02-23","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":337,"armGroups":[{"label":"Metformin 500 mg q.d.","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Metformin","Drug: Placebo"]},{"label":"Metformin 250 mg b.i.d.","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Metformin","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Sitagliptin","Drug: Placebo"]}],"interventions":[{"name":"Sitagliptin","otherNames":["MK-0431/ONO-5435"]},{"name":"Metformin","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 Diabetes Mellitus (T2DM)\n* Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 4 weeks, on any additional oral hypoglycemic agent (AHA) in the prior 8 weeks, and HbA1c ≥ 6.0% and ≤ 9.0%; or\n* Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 10 weeks, not on any additional oral AHA in the prior 8 weeks, and HbA1c ≥ 6.5% and \\< 10.0%\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus,\n* Secondary diabetes mellitus, or\n* Gestational diabetes mellitus","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)","description":"Based on a constrained longitudinal data analysis (cLDA) model with terms for treatment, other prior antihyperglycemic agent (AHA) therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.434","spread":null},{"groupId":"OG001","value":"-0.587","spread":null},{"groupId":"OG002","value":"0.091","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)","description":"Based on a cLDA model with terms for treatment, other prior AHA therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.02","spread":null},{"groupId":"OG001","value":"-11.27","spread":null},{"groupId":"OG002","value":"7.32","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null},{"groupId":"OG001","value":"67.7","spread":null},{"groupId":"OG002","value":"60.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":138},"commonTop":["Nasopharyngitis","Constipation","Upper respiratory tract infection"]}}}